ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

NIH Probing: Double Dipping” Allegation

September 4, 1981

Sirolimus-Containing Therapy Reduces GVHD, Study Finds

January 31, 2003

US Oncology Renegotiates Affiliations, Converts Practices To Earnings Model.

November 30, 2001

Katterhagen Predicts Increase Support From State, Local sources, Sees It As Community Challenge

March 27, 1981

Cancer Prevention Grants Awarded To Five States, DC

June 30, 1989

Copyright Violation Of Cancer Letter – Results In Payment

July 19, 1991